Company / Cost of Revenue
MADRIGAL PHARMACEUTICALS, INC. Cost of Revenue History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.2M
FY2024
5-year range
$0 / $6.2M
FY2022-FY2024
Trend
-
vs FY2023
Sector context
#74 of 85
Health Care
What the data says
MADRIGAL PHARMACEUTICALS, INC.'s cost of revenue of $6M is lower than 87% of companies in the Health Care sector (FY2024). Increased from $0 to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2024.
Increased from $0 to $6M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 85This company $6.2M Sector average $2.0B
▼
-99.7% below sector average
Key checks
Key Insights
- Ranks #74 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $6.2M | - |
| FY2023 | $0 | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Mar 29, 2026